Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.41 |
| ▸ | ADORA2A | P29274 | 8/20 | 0.41 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3163330 | 0.91 | NPSR1 (0.48) | MEN1KMT2AALDH1A1 | |
| SCHEMBL3168515 | 0.90 | ADORA1 (0.42) | ADORA1ADORA3ADORA2AADORA2BKCNH2 | |
| SCHEMBL3161449 | 0.89 | DRD4 (0.49) | MEN1KMT2AALDH1A1ATMADORA1 | |
| SCHEMBL3164709 | 0.88 | NPC1 (0.47) | MEN1KMT2AALDH1A1ADORA1ADORA3 | |
| SCHEMBL3163125 | 0.88 | NPC1 (0.47) | MEN1KMT2AALDH1A1ADORA1ADORA3 | |
| SCHEMBL3171949 | 0.88 | PARP1 (0.47) | MEN1KMT2AALDH1A1ATMADORA1 | |
| SCHEMBL3162785 | 0.87 | MEN1 (0.54) | MEN1KMT2AALDH1A1 | |
| SCHEMBL3156155 | 0.87 | MEN1 (0.43) | MEN1KMT2AALDH1A1 | |
| SCHEMBL3155645 | 0.87 | SMN1; SMN2 (0.40) | MEN1KMT2AALDH1A1ADORA1ADORA3 | |
| SCHEMBL3169937 | 0.87 | ALDH1A1 (0.48) | ALDH1A1ADORA1ADORA3ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465631-B1 | PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE | OSI PHARM INC (US) | 2010-02-24 | — | — | EP | disclosed |